Advanced Materials · 2025 · 55 citations · 38 references
Life SciencesOncologyPharmacologyMitochondrial BiologyMolecular OncologyNanomaterialsMitochondrial Stress ResponsesNanocarriers For TherapeuticsNanomedicineNanoparticle DesignPhotodynamic TherapyTheranostic NanoparticlesCancer Photodynamic TherapyMesoporous NanomaterialsMesoporous Silica NanomaterialsMesoporous Silica NanoparticlesMitochondrial Oxidative StressMitochondrial Targeting Of NanoparticlesMolecular TargetingPhotodynamic Therapy Nanomaterials
CGAS-STING agonists generally lead to hyperimmunity and systemic toxicity, hindering their immunotherapeutic outcomes. Herein, a mitochondrion-targeted nanoagonist (termed HABH) containing boron dipyrromethene (BODIPY)-derived type I photosensitizer (BDP) and Au nanoparticle-engineered hollow mesoporous silica (HMSN/AuNPs) has been fabricated for light-controlled mitochondrial stress-inducing and agonist-independent cGAS-STING pathway activation. The HABH nanoagonist can actively target tumor tissues and release the mitochondrion-targeted BDP. Under light illumination, BDP achieves type I photodynamic therapy (PDT) in mitochondria, generating massive hydroxyl radicals (•OH) and inducing mitochondrial stress in an oxygen-independent manner, promoting the release of mitochondrial DNA (mtDNA). Simultaneously, the HMSN/AuNPs act as dual nanozymes to derive cascade reactions for •OH production, elevating the intracellular oxidative state, and together with the BDP-induced mitochondrial stress, finally evoking the cGAS-STING pathway and facilitating the release of type I interferon. In the orthotopic breast tumor models, the HABH nanoagonist achieved intratumoral and systemic immunoactivation for eradicating primary tumors and preventing metastasis tumors. Therefore, the constructed mitochondrion-targeted nanoagonist enabled light-controlled and agonist-independent cGAS-STING activation, providing a paradigm for photoimmunotherapy.
38
STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors
Seng‐Ryong Woo, Mercedes B. Fuertes, Leticia Corrales et al. · Immunity · 2014 · 1.8K citations · Full text
Life Sciences, Immunology, Oncology +12
An orally available non-nucleotide STING agonist with antitumor activity
Bo‐Sheng Pan, Samanthi A. Perera, Jennifer Piesvaux et al. · Science · 2020 · 660 citations
Glucose-oxidase like catalytic mechanism of noble metal nanozymes
Jinxing Chen, Ma Qian, Minghua Li et al. · Nature Communications · 2021 · 483 citations · Full text